

# Synthesis of New Methano[1,5]dioxocines *via* a Domino Reaction of 4-Hydroxy-2*H*-pyran-2-ones / 4-Hydroxy-2*H*-chromen-2-ones with Acyclic 1,3-Diketones

Heiko Leutbecher, Jürgen Conrad, and Uwe Beifuss

Bioorganische Chemie, Institut für Chemie, Universität Hohenheim, Garbenstraße 30, D-70599 Stuttgart, Germany

Reprint requests to Prof. Dr. U. Beifuss. Fax: (+49)711-459-22951.

E-mail: ubeifuss@uni-hohenheim.de


*Z. Naturforsch.* **2008**, *63b*, 871 – 876; received February 23, 2008

New methano[1,5]dioxocines, *O*-heterocycles with a framework similar to Tröger's base, were prepared by means of a three-component reaction. The scope of this domino reaction was studied.

**Key words:** Domino Reactions, Tröger's Base, *O*-Heterocycles


## Introduction

Tröger's base, which was first prepared by Julius Tröger more than a century ago [1], is a molecule with a fascinating structure [2], for which some decades later Spielman was able to establish its bridged methano[1,5]diazocine pattern [3]. The chirality of the chiral heterocyclic amine with  $C_2$  symmetry is due to the presence of two stereogenic nitrogen atoms.




Tröger's base

Since the discovery of Tröger's base numerous structural analogs with a central [1,5]diazocine skeleton were synthesized [3,4]. Both the chirality and the rigid concave structure of the methano[1,5]diazocine skeleton are the reasons why Tröger's base and derivatives thereof have found interest in the design of receptors for the molecular recognition of neutral molecules [5], as chiral solvating agents [6], and in the field of asymmetric synthesis [7].




The 2,6-methano[1,5]dioxocine skeleton

Oxo analogs like the 2,6-methano[1,5]dioxocine belong to the same symmetry group as the [1,5]diazocines. One method for the preparation of this unusual skeleton is based on the acid-catalyzed reaction of salicylaldehydes with either *o*-vinylphenols or



*o*-coumaric acids [8]. Another approach relies on the conversion of suitably substituted flavylum salts [9]. And finally, using the Moreno-Mañas method, methano[1,5]dioxocines can be made accessible by reacting two equivalents of a cyclic 1,3-dicarbonyl compound with one equivalent of an acyclic 1,3-diketone. The synthesis of 3,6,9,12-tetramethyl-1*H*,6*H*,7*H*,12*H*-6,12-methanodipyran[4,3-*b*:4,3-*f*]dioxocin-1,7-dione (**3a**) [10] and 7,15-dimethyl-7,15-methano-6*H*,7*H*,14*H*,15*H*-[1,5]dioxocino[3,2-*c*:7,6-*c'*]bis[1]benzopyran-6,14-dione (**5a**) [11] could be achieved by reaction of 4-hydroxy-6-methyl-2*H*-pyran-2-one (**1a**) and 4-hydroxy-2*H*-chromen-2-one (**4a**), respectively, with 2,4-pentanedione (**2a**). A common feature of all the methods published so far is that only little is known concerning their scope and limitations.

Entry	Equiv. of <b>1a</b>	Equiv. of <b>2a</b>	Solvent	<i>T</i> (°C)	Time (h)	Yield of <b>3a</b> (%)
1	2	1	1-nitropropane	110	18	20
2	2	1	1,1,2-trichloroethane	110	18	23
3	1	2	1,1,2-trichloroethane	110	22.5	38
4	1	1	1,1,2-trichloroethane	110	15	53
5	1	2	toluene	110	16	77

Table 1. Domino reactions of **1a** with **2a** under different reaction conditions.

Scheme 1.

In the context of our studies on domino reactions of 4-hydroxy-2*H*-pyran-2-ones and related compounds [12] we were encouraged by Moreno-Mañas's elegant approach to methano[1,5]dioxocines to study the scope of this domino reaction and to optimize the reaction conditions. Here we present our studies on the reaction of 4-hydroxy-6-methyl-2*H*-pyran-2-one (**1a**), 4-hydroxy-2*H*-chromen-2-one (**4a**) and related compounds with several 1,3-diketones to give new compounds with a 2,6-methano[1,5]dioxocine skeleton (Scheme 1).

## Results and Discussion


Based on our experience with domino reactions of 4-hydroxy-2*H*-pyran-2-ones and related compounds we set out to study the influence of the reaction conditions on the reaction between 4-hydroxy-6-methyl-2*H*-pyran-2-one (**1a**) and 2,4-pentanedione (**2a**) (Table 1). When 2 equivs. of **1a** and 1 equiv. of **2a** were reacted in the presence of catalytic amounts of pyridine in solvents like ethanol, *iso*-propanol and THF at 110 °C in a sealed tube, only the decomposition of **1a** was observed. In 1-nitropropane and 1,1,2-trichloroethane as a solvent, however, the product **3a** was

Table 2. Reactions of **1a** and **4a** with the acyclic 1,3-diketones **2a–c**.

Entry	Pyrone / Coumarin	1,3-Diketone	$R^1$	$R^2$	Product	Yield (%)
1	<b>1a</b>	<b>2a</b>	Me	H	<b>3a</b>	77
2	<b>1a</b>	<b>2b</b>	Me	Me	<b>3b</b>	16
3	<b>1a</b>	<b>2c</b>	Et	H	<b>3c</b>	11
4	<b>4a</b>	<b>2a</b>	Me	H	<b>5a</b>	80
5	<b>4a</b>	<b>2b</b>	Me	Me	<b>5b</b>	31
6	<b>4a</b>	<b>2c</b>	Et	H	<b>5c</b>	51

formed with yields of 20 and 23 %, respectively (Table 1, entries 1 and 2). In 1,1,2-trichloroethane, the yield of **3a** could be further enhanced to 38 and 53 %, respectively, by increasing the amount of **2a** (Table 1, entries 3 and 4).

The best results were obtained with toluene as a solvent. So the methano[1,5]dioxocine **3a** was isolated in 77 % yield when 1 equiv. of 4-hydroxy-6-methyl-2*H*-pyran-2-one (**1a**) and 2 equivs. of 2,4-pentanedione (**2a**) were reacted with catalytic amounts of pyridine in toluene as a solvent at 110 °C (Table 1, entry 5 and Table 2, entry 1). Upon the reaction of 4-hydroxy-2*H*-chromen-2-one (**4a**) and **2a** under the reaction conditions developed in our laboratory the benzopyrano annulated methano[1,5]dioxocine **5a** was





Scheme 2.

formed with even higher yields (80%) (Table 2, entry 4). The influence of toluene as a solvent is remarkable as the products are formed with considerably lower yields when the transformations are performed without any solvent [10, 11]. For example, Moreno-Mañas *et al.* achieved the synthesis of **3a** in 62% yield upon reaction of **1a** with a large excess (> 8 equivs.) of **2a** in the presence of catalytic amounts of pyridine [10]. Under similar conditions Talapatra *et al.* obtained **5a** in 68% yield [11]. Experiments to run the three-component reaction of **1a** and **2a** under microwave conditions failed as decomposition was observed at temperatures exceeding 130 °C.

This is why we focussed on the scope of the domino reaction. We found that 4-hydroxy-6-methyl-2H-pyran-2-one (**1a**) as well as 4-hydroxy-2H-chromen-2-one (**4a**) react with 3-methyl-2,4-pentanedione (**2b**) and 3,5-heptanedione (**2c**) to give the expected heterocycles **3b, c** and **5b, c** (Table 2). The pyran derivatives **3b** and **3c** were isolated with yields of 16 and 11%, respectively (Table 2, entries 2 and 3), and the corresponding benzopyran derivatives **5b** and **5c** were obtained in 31 and 51% yield, respectively (Table 2, entries 5 and 6). These results indicate that a) the yields of the transformations with **4a** were higher than those with **1a** and b) the yields of the reactions with **2b** and **2c** were generally lower than those of the transformations of **1a** and **4a** with 2,4-pentanedione (**2a**).

Apart from the lower reactivity of **2b** and **2c**, the yields of **3b, c** and **5b, c** are considerably diminished through losses upon purification of the products by means of column chromatography. In contrast, **3a** and **5a** crystallized from the corresponding reaction mixture in high purity.



We then tried to react 4-hydroxy-2H-pyran-2-one **1a** with additional 1,3-diketones in terms of the multicomponent reaction presented here. While dibenzoylmethane (**2d**) did not react with **1a** at all, the reaction of **1a** with 1,1,1,5,5,5-hexafluoro-2,4-pentanedione (**2e**) afforded a product that could not be isolated in pure form.

Finally, our focus was on the variation of the reaction partners of 1,3-diketones. The reaction of 4-hydroxy-7-methoxy-2H-chromen-2-one (**4b**) with 2,4-pentanedione (**2a**) was successful, and the expected methano[1,5]dioxocine **5d** was isolated in 20% yield (Scheme 2). Using our protocol we were not able, though, to react 4-hydroxy-6-phenyl-2H-pyran-2-one (**1b**), 1,3,5-trihydroxybenzene (**6**), 2,4-dihydropyridine (**7**), 4,6-dihydropyrimidine (**8**) or 2,4-dihydroxyquinoline (**9**) with **2a**.

## Conclusion

In summary, the reactions of 4-hydroxy-6-methyl-2H-pyran-2-one (**1a**), 4-hydroxy-2H-chromen-2-one (**4a**) as well as several other cyclic 1,3-dicarbonyls with a number of acyclic 1,3-diketones **2** under basic conditions have been found to yield a number of new methano[1,5]dioxocines. Although a number of methano[1,5]dioxocines could be made accessible in good yields by developing suitable reaction conditions, the scope of this unusual domino reaction seems to be rather narrow.

## Experimental Section

### General

Commercial reagents were used without further purification. All solvents were distilled prior to use. Flash chromatography was performed on silica gel 60 (0.040–0.063 mm) (Baker). Melting points (Büchi B-545) are uncorrected. TLC: silica gel SIL G/UV<sub>254</sub> (Macherey-Nagel). UV/Vis: Carey 4 E (Varian). FT-IR: Spectrum One (Perkin Elmer) (ATR). NMR: Varian Unity INOVA (300/75 MHz and 500/125 MHz, respectively). EIMS: 70 eV, MAT 8200 (Finnigan MAT). Elemental analyses: Microanalytical laboratory of the University of Göttingen.

### Typical procedure for the synthesis of the methano[1,5]dioxocines **3a–c** and **5a–d**

A mixture of 0.368 g (2.27 mmol) 4-hydroxy-2H-chromen-2-one (**4a**) and 0.587 mg (4.58 mmol) of 3,5-heptanedione (**2c**) in 5 mL of toluene was treated with 5 drops of pyridine and refluxed for 16 h. The solvent was removed *in vacuo* and the resulting residue purified via flash chromatography on silica gel (Et<sub>2</sub>O) to give 0.243 g (51 %) 7,15-diethyl-7,15-methano-6H,7H,14H,15H-[1,5]dioxocino[3,2-*c*:7,6-*c'*]bis[1]benzopyran-6,14-dione (**5c**) in analytically pure form.

Compounds **3a** and **5a** crystallized from the reaction mixture in high purity when **1a** and **4a**, respectively, were reacted with **2a**. The crystals were filtered, washed with Et<sub>2</sub>O and dried.

### (6*RS*,12*RS*)-3,6,9,12-Tetramethyl-1H,6H,7H,12H-6,12-methanodipyran[4,3-*b*:4,3-*f'*][1,5]dioxocin-1,7-dione (**3a**)

M.p. 246–248 °C (methanol; dec.; lit. [10]: 235–237 °C). – *R*<sub>f</sub> = 0.33 (SiO<sub>2</sub>; Et<sub>2</sub>O). – <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ = 2.00 (s, 6 H, 6-CH<sub>3</sub>, 12-CH<sub>3</sub>), 2.06 (s, 2 H, 13-H<sub>2</sub>), 2.15 (s, 6 H, 3-CH<sub>3</sub>, 9-CH<sub>3</sub>), 5.80 (s, 2 H, 4-H, 10-H). – <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>): δ = 20.14 (3-CH<sub>3</sub>, 9-CH<sub>3</sub>), 23.07 (6-CH<sub>3</sub>, 12-CH<sub>3</sub>), 43.98 (C-13), 73.63 (C-6, C-12), 99.47 (C-6a, C-12a), 100.28 (C-4, C-10), 162.02 (C-1, C-7), 163.35 (C-3, C-9), 167.47 (C-4a, C-10a). – MS (EI, 70 eV): *m/z* (%) = 316 (100) [M]<sup>+</sup>, 301 (71) [M–CH<sub>3</sub>]<sup>+</sup>, 217 (26), 204 (18), 191 (24), 164 (71), 153 (14), 85 (15), 43 (40).

### (6*RS*,12*RS*)-3,6,9,12,13-Pentamethyl-1H,6H,7H,12H-6,12-methanodipyran[4,3-*b*:4,3-*f'*][1,5]dioxocin-1,7-dione (**3b**)

M.p. 228 °C (methanol/H<sub>2</sub>O; dec.). – *R*<sub>f</sub> = 0.41 (SiO<sub>2</sub>; Et<sub>2</sub>O). – UV/Vis (CH<sub>3</sub>CN): λ<sub>max</sub> (lg ε<sub>max</sub>) = 206 (4.60), 285 nm (4.05). – IR (ATR): ν = 2935 (CH<sub>3</sub>), 1703 (C=O), 1641 (C=C), 1447 and 1386 (CH<sub>3</sub>), 1227 and 1052 (C–O), 829 cm<sup>–1</sup> (=C–H). – <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ = 0.98 (d, <sup>3</sup>J<sub>13–CH<sub>3</sub>,13–H</sub> = 7.0 Hz, 3 H, 13-CH<sub>3</sub>), 1.85 (q,

<sup>3</sup>J<sub>13–H,13–CH<sub>3</sub></sub> = 7.0 Hz, 1 H, 13-H), 1.936 (s, 3 H, 6-CH<sub>3</sub> or 12-CH<sub>3</sub>), 1.941 (s, 3 H, 6-CH<sub>3</sub> or 12-CH<sub>3</sub>), 2.14 (s, 6 H, 3-CH<sub>3</sub>, 9-CH<sub>3</sub>), 5.77 (s, 1 H, 4-H or 10-H), 5.78 (s, 1 H, 4-H or 10-H). – <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>): δ = 9.11 (13-CH<sub>3</sub>), 19.36 (6-CH<sub>3</sub> or 12-CH<sub>3</sub>), 20.08 (3-CH<sub>3</sub> or 9-CH<sub>3</sub>), 20.10 (3-CH<sub>3</sub> or 9-CH<sub>3</sub>), 22.22 (6-CH<sub>3</sub> or 12-CH<sub>3</sub>), 43.07 (C-13), 75.73 (C-6, C-12), 97.46 (C-6a, C-12a), 100.08 (C-4 or C-10), 100.23 (C-4 or C-10), 162.09, 162.43 (C-1, C-7, C-4a or C-10a), 163.28 (C-3 or C-9), 163.33 (C-3 or C-9), 166.87, 167.31 (C-1, C-7, C-4a or C-10a). – MS (EI, 70 eV): *m/z* (%) = 330 (72) [M]<sup>+</sup>, 315 (54) [M–CH<sub>3</sub>]<sup>+</sup>, 287 (6), 246 (30), 231 (26), 218 (53), 205 (53), 178 (32), 134 (17), 119 (7), 85 (26), 67 (28), 43 (100). – C<sub>18</sub>H<sub>18</sub>O<sub>6</sub> (330.36): calcd. C 65.45, H 5.49; found C 65.22, H 5.20.

### (6*RS*,12*RS*)-6,12-Diethyl-3,9-dimethyl-1H,6H,7H,12H-6,12-methanodipyran[4,3-*b*:4,3-*f'*][1,5]dioxocin-1,7-dione (**3c**)

M.p. 197 °C. – *R*<sub>f</sub> = 0.42 (SiO<sub>2</sub>; Et<sub>2</sub>O). – UV/Vis (CH<sub>3</sub>CN): λ<sub>max</sub> (lg ε<sub>max</sub>) = 206 (4.62), 286 nm (4.05). – IR (ATR): ν = 2967 (CH<sub>2</sub>, CH<sub>3</sub>), 1706 (C=O), 1644 (C=C), 1448 (CH<sub>2</sub>, CH<sub>3</sub>), 1385 (CH<sub>3</sub>), 1219 and 1070 (C–O), 840 cm<sup>–1</sup> (=C–H). – <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): δ = 0.91 (t, <sup>3</sup>J<sub>2'–H<sub>3</sub>,1'–H<sub>2</sub></sub> = <sup>3</sup>J<sub>2''–H<sub>3</sub>,1''–H<sub>2</sub></sub> = 7.6 Hz, 6 H, 2'-H<sub>3</sub>, 2''-H<sub>3</sub>), 2.00 (s, 2 H, 13-H<sub>2</sub>), 2.16 (s, 6 H, 3-CH<sub>3</sub>, 9-CH<sub>3</sub>), 2.31 (dq, <sup>2</sup>J<sub>1'–H<sub>A</sub>,1'–H<sub>B</sub></sub> = <sup>2</sup>J<sub>1''–H<sub>A</sub>,1''–H<sub>B</sub></sub> = 13.9 Hz, <sup>3</sup>J<sub>1'–H<sub>A</sub>,2'–H<sub>3</sub></sub> = <sup>3</sup>J<sub>1''–H<sub>A</sub>,2''–H<sub>3</sub></sub> = 7.6 Hz, 2 H, 1'-H<sub>A</sub>, 1''-H<sub>A</sub>), 2.80 (dq, <sup>2</sup>J<sub>1'–H<sub>B</sub>,1'–H<sub>A</sub></sub> = <sup>2</sup>J<sub>1''–H<sub>B</sub>,1''–H<sub>A</sub></sub> = 13.7 Hz, <sup>3</sup>J<sub>1'–H<sub>B</sub>,2'–H<sub>3</sub></sub> = <sup>3</sup>J<sub>1''–H<sub>B</sub>,2''–H<sub>3</sub></sub> = 7.6 Hz, 2 H, 1'-H<sub>B</sub>, 1''-H<sub>B</sub>), 5.81 (s, 2 H, 4-H, 10-H). – <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>): δ = 8.64 (C-2', C-2''), 20.11 (3-CH<sub>3</sub>, 9-CH<sub>3</sub>), 27.92 (C-1', C-1''), 36.45 (C-13), 76.96 (C-6, C-12), 98.30 (C-6a, C-12a), 100.46 (C-4, C-10), 161.87 (C-1, C-7), 163.35 (C-3, C-9), 168.65 (C-4a, C-10a). – MS (EI, 70 eV): *m/z* (%) = 344 (28) [M]<sup>+</sup>, 315 (100) [M–C<sub>2</sub>H<sub>5</sub>]<sup>+</sup>, 301 (4), 273 (1), 259 (2), 231 (21), 203 (4), 178 (30), 85 (10), 69 (6). – C<sub>19</sub>H<sub>20</sub>O<sub>6</sub> (344.36): calcd. C 66.27, H 5.85; found C 66.03, H 5.80.

### (7*RS*,15*RS*)-7,15-Dimethyl-7,15-methano-6H,7H,14H,15H-[1,5]dioxocino[3,2-*c*:7,6-*c'*]bis[1]benzopyran-6,14-dione (**5a**)

M.p. 259–261 °C (CH<sub>2</sub>Cl<sub>2</sub>/PE; dec.; lit. [11]: 255 °C). – *R*<sub>f</sub> = 0.35 (SiO<sub>2</sub>; *tert*-butyl methyl ether/PE = 1:1). – <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ = 2.22 (s, 6 H, 7-CH<sub>3</sub>, 15-CH<sub>3</sub>), 2.31 (s, 2 H, 17-H<sub>2</sub>), 7.20–7.29 (m, 4 H, 2-H, 10-H, 4-H, 12-H), 7.53 (td, <sup>3</sup>J<sub>3–H,2–H</sub> = <sup>3</sup>J<sub>3–H,4–H</sub> = <sup>3</sup>J<sub>11–H,10–H</sub> = <sup>3</sup>J<sub>11–H,12–H</sub> = 7.8 Hz, <sup>4</sup>J<sub>3–H,1–H</sub> = <sup>4</sup>J<sub>11–H,9–H</sub> = 1.5 Hz, 2 H, 3-H, 11-H), 7.94 (dd, <sup>3</sup>J<sub>1–H,2–H</sub> = <sup>3</sup>J<sub>9–H,10–H</sub> = 8.0 Hz, <sup>4</sup>J<sub>1–H,3–H</sub> = <sup>4</sup>J<sub>9–H,11–H</sub> = 1.4 Hz, 2 H, 1-H, 9-H). – <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>): δ = 23.45 (7-CH<sub>3</sub>, 15-CH<sub>3</sub>), 44.33 (C-17), 74.45 (C-7, C-15), 102.03 (C-6a, C-14a), 114.95 (C-8b, C-16b), 116.56 (C-4, C-12), 124.34 (C-2,

C-10), 124.46 (C-1, C-9), 133.42 (C-3, C-11), 153.32 (C-4a, C-12a), 160.15 (C-6, C-14), 162.99 (C-8a, C-16a). – MS (EI, 70 eV):  $m/z$  (%) = 388 (59)  $[M]^+$ , 373 (41)  $[M-CH_3]^+$ , 253 (19), 226 (20), 200 (100), 121 (33), 92 (7).

(7*RS*,15*RS*)-7,15,17-Trimethyl-7,15-methano-6*H*,7*H*,14*H*,15*H*-[1,5]dioxocino[3,2-*c*:7,6-*c'*]bis[1]benzopyran-6,14-dione (**5b**)

M.p. 208 °C (dec.). –  $R_f$  = 0.61 (SiO<sub>2</sub>; Et<sub>2</sub>O). – UV/Vis (CH<sub>3</sub>CN):  $\lambda_{max}$  (lg  $\epsilon_{max}$ ) = 212 (4.66), 267 (4.22), 281 (4.09), 308 nm (4.12). – IR (ATR):  $\nu$  = 3068 (=C–H), 2932 (CH<sub>3</sub>), 1716 (C=O), 1614, 1565 and 1492 (C=C), 1454, 1387 (CH<sub>3</sub>), 1235 and 1067 (C–O), 760 cm<sup>–1</sup> (=C–H, 1,2-disub. ar.). – <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>):  $\delta$  = 1.16 (d, <sup>3</sup> $J_{17-CH_3,17-H}$  = 7.0 Hz, 3 H, 17-CH<sub>3</sub>), 2.14 (q, <sup>3</sup> $J_{17-H,17-CH_3}$  = 7.0 Hz, 1 H, 17-H), 2.20 (s, 3 H, 7-CH<sub>3</sub> or 15-CH<sub>3</sub>), 2.21 (s, 3 H, 7-CH<sub>3</sub> or 15-CH<sub>3</sub>), 7.22–7.32 (m, 4 H, 2-H, 10-H, 4-H, 12-H), 7.52–7.60 (m, 2 H, 3-H, 11-H), 7.92–8.00 (m, 2 H, 1-H, 9-H). – <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>):  $\delta$  = 9.31 (17-CH<sub>3</sub>), 19.76 (7-CH<sub>3</sub> or 15-CH<sub>3</sub>), 22.66 (7-CH<sub>3</sub> or 15-CH<sub>3</sub>), 43.46 (C-17), 76.62 (C-7 or C-15), 78.20 (C-7 or C-15), 100.09 (C-6a or C-14a), 102.97 (C-6a or C-14a), 114.95 (C-8b or C-16b), 114.94 (C-8b or C-16b), 116.50 (C-4 or C-12), 116.55 (C-4 or C-12), 124.28, 124.34, 124.48 (C-1, C-9, C-2 or C-10), 133.42 (C-3, C-11), 153.37 (C-4a, C-12a), 160.18 (C-6 or C-14), 160.50 (C-6 or C-14), 162.34 (C-8a or C-16a), 162.84 (C-8a or C-16a). – MS (EI, 70 eV):  $m/z$  (%) = 402 (41)  $[M]^+$ , 387 (20)  $[M-CH_3]^+$ , 282 (16), 241 (20), 214 (31), 121 (100), 92 (52), 67 (31), 65 (30). – HRMS (EI, 70 eV):  $m/z$  = 402.11195 (calcd. 402.11035 for C<sub>15</sub>H<sub>24</sub>O<sub>3</sub>,  $[M]^+$ ).

(7*RS*,15*RS*)-7,15-Diethyl-7,15-methano-6*H*,7*H*,14*H*,15*H*-[1,5]dioxocino[3,2-*c*:7,6-*c'*]bis[1]benzopyran-6,14-dione (**5c**)

M.p. 204 °C (dec.). –  $R_f$  = 0.65 (SiO<sub>2</sub>; Et<sub>2</sub>O). – UV/Vis (CH<sub>3</sub>CN):  $\lambda_{max}$  (lg  $\epsilon_{max}$ ) = 213 (4.65), 268 (4.22), 281 (4.09), 309 nm (4.12). – IR (ATR):  $\nu$  = 2924 (CH<sub>2</sub>, CH<sub>3</sub>), 1713 (C=O), 1612, 1560 and 1492 (C=C), 1454 (CH<sub>2</sub>, CH<sub>3</sub>), 1391 (CH<sub>3</sub>), 1229 and 1073 (C–O), 761 cm<sup>–1</sup> (=C–H, 1,2-disub. ar.). – <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>):  $\delta$  = 1.03 (t, <sup>3</sup> $J_{2'-H_3,1'-H_2}$  = <sup>3</sup> $J_{2''-H_3,1''-H_2}$  = 7.6 Hz, 6 H, 2'-H<sub>3</sub>, 2''-H<sub>3</sub>), 2.27 (s, 2 H, 17-H<sub>2</sub>), 2.54 (dq, <sup>2</sup> $J_{1'-H_A,1'-H_B}$  = <sup>2</sup> $J_{1''-H_A,1''-H_B}$  = 13.8 Hz, <sup>3</sup> $J_{1'-H_A,2'-H_3}$  = <sup>3</sup> $J_{1''-H_A,2''-H_3}$  = 7.5 Hz, 2 H, 1'-H<sub>A</sub>, 1''-H<sub>A</sub>), 3.09 (dq, <sup>2</sup> $J_{1'-H_B,1'-H_A}$  = <sup>2</sup> $J_{1''-H_B,1''-H_A}$  = 13.9 Hz,

<sup>3</sup> $J_{1'-H_B,2'-H_3}$  = <sup>3</sup> $J_{1''-H_B,2''-H_3}$  = 7.6 Hz, 2 H, 1'-H<sub>B</sub>, 1''-H<sub>B</sub>), 7.24 (d, <sup>3</sup> $J_{4-H,3-H}$  = <sup>3</sup> $J_{12-H,11-H}$  = 8.3 Hz, 2 H, 4-H, 12-H), 7.27 (t, <sup>3</sup> $J_{2-H,1-H}$  = <sup>3</sup> $J_{2-H,3-H}$  = <sup>3</sup> $J_{10-H,9-H}$  = <sup>3</sup> $J_{10-H,11-H}$  = 7.7 Hz, 2 H, 2-H, 10-H), 7.54 (td, <sup>3</sup> $J_{3-H,2-H}$  = <sup>3</sup> $J_{3-H,4-H}$  = <sup>3</sup> $J_{11-H,10-H}$  = <sup>3</sup> $J_{11-H,12-H}$  = 7.8 Hz, <sup>4</sup> $J_{3-H,1-H}$  = <sup>4</sup> $J_{11-H,9-H}$  = 1.5 Hz, 2 H, 3-H, 11-H), 7.94 (dd, <sup>3</sup> $J_{1-H,2-H}$  = <sup>3</sup> $J_{9-H,10-H}$  = 7.9 Hz, <sup>4</sup> $J_{1-H,3-H}$  = <sup>4</sup> $J_{9-H,11-H}$  = 1.5 Hz, 2 H, 1-H, 9-H). – <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>):  $\delta$  = 8.82 (C-2', C-2''), 28.26 (C-1', C-1''), 36.94 (C-17), 77.75 (C-7, C-15), 100.86 (C-6a, C-14a), 115.05 (C-8b, C-16b), 116.52 (C-4, C-12), 124.30 (C-1, C-9 or C-2, C-10), 124.36 (C-1, C-9 or C-2, C-10), 133.36 (C-3, C-11), 153.36 (C-4a, C-12a), 160.00 (C-6, C-14), 164.14 (C-8a, C-16a). – MS (EI, 70 eV):  $m/z$  (%) = 416 (29)  $[M]^+$ , 387 (100)  $[M-C_2H_5]^+$ , 267 (10), 254 (8), 214 (52), 201 (6), 175 (6), 121 (36). – HRMS (EI, 70 eV):  $m/z$  = 416.12418 (calcd. 416.12598 for C<sub>15</sub>H<sub>24</sub>O<sub>3</sub>,  $[M]^+$ ).

(7*RS*,15*RS*)-3,11-Dimethoxy-7,15-dimethyl-7,15-methano-6*H*,7*H*,14*H*,15*H*-[1,5]dioxocino[3,2-*c*:7,6-*c'*]bis[1]benzopyran-6,14-dione (**5d**)

M.p. 219 °C (dec.). –  $R_f$  = 0.50 (SiO<sub>2</sub>; *tert*-butyl methyl ether). – UV/Vis (CH<sub>3</sub>CN):  $\lambda_{max}$  (lg  $\epsilon_{max}$ ) = 206 (4.83), 219 (4.55), 284 (4.16), 313 (4.47), 325 nm (4.37). – IR (ATR):  $\nu$  = 2924, 2852 (CH<sub>2</sub>, CH<sub>3</sub>), 1710 (C=O), 1607 and 1561 (C=C), 1439 (CH<sub>2</sub>, CH<sub>3</sub>), 1379 (CH<sub>3</sub>), 1201 and 1069 (C–O), 831 cm<sup>–1</sup> (=C–H). – <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>):  $\delta$  = 2.18 (s, 6 H, 7-CH<sub>3</sub>, 15-CH<sub>3</sub>), 2.27 (s, 2 H, 17-H<sub>2</sub>), 3.83 (s, 6 H, 3-OCH<sub>3</sub>, 11-OCH<sub>3</sub>), 6.69 (d, <sup>4</sup> $J_{4-H,2-H}$  = <sup>4</sup> $J_{12-H,10-H}$  = 2.2 Hz, 2 H, 4-H, 12-H), 6.80 (dd, <sup>3</sup> $J_{2-H,1-H}$  = <sup>3</sup> $J_{10-H,9-H}$  = 8.9 Hz, <sup>4</sup> $J_{2-H,4-H}$  = <sup>4</sup> $J_{10-H,12-H}$  = 2.3 Hz, 2 H, 2-H, 10-H), 7.80 (d, <sup>3</sup> $J_{1-H,2-H}$  = <sup>3</sup> $J_{9-H,10-H}$  = 8.9 Hz, 2 H, 1-H, 9-H). – <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>):  $\delta$  = 23.60 (7-CH<sub>3</sub>, 15-CH<sub>3</sub>), 44.48 (C-17), 56.02 (3-OCH<sub>3</sub>, 11-OCH<sub>3</sub>), 74.44 (C-7, C-15), 99.58 (C-6a, C-14a), 100.23 (C-4, C-12), 108.18 (C-8b, C-16b), 112.60 (C-2, C-10), 125.63 (C-1, C-9), 155.18 (C-4a, C-12a), 160.64, 163.29 (C-6, C-14 or C-8a, C-16a), 164.10 (C-3, C-11). – MS (EI, 70 eV):  $m/z$  (%) = 448 (45)  $[M]^+$ , 433 (24)  $[M-CH_3]^+$ , 283 (8), 256 (10), 230 (100), 151 (35), 107 (5), 79 (4). – HRMS (EI, 70 eV):  $m/z$  = 448.11547 (calcd. 448.11581 for C<sub>15</sub>H<sub>24</sub>O<sub>3</sub>,  $[M]^+$ ).

#### Acknowledgements

We are grateful to Ms. S. Mika for NMR spectra and to Ms. I. Klaiber for mass spectra.

[1] J. Tröger, *J. Prakt. Chem.* **1887**, 36, 225.

[2] a) M. Valík, R. M. Strongin, V. Král, *Supramol. Chem.* **2005**, 17, 347; b) M. Demeunynck, A. Tatibouët in *Progress in Heterocyclic Chemistry*, Vol. 11 (Eds.:

G. W. Gribble, T. L. Gilchrist), Elsevier Science Ltd., Kidlington, Oxford **1999**, pp. 1–20.

[3] M. A. Spielman, *J. Am. Chem. Soc.* **1935**, 57, 583.

[4] a) R. Abonia, A. Alborno, H. Larrahondo, J. Quiroga,

- B. Insuasty, H. Insuasty, A. Hormaza, A. Sánchez, M. Nogueras, *J. Chem. Soc., Perkin Trans. 1* **2002**, 1588; b) J. Cudero, C. Pardo, M. Ramos, E. Gutierrez-Puebla, A. Monge, J. Elguero, *Tetrahedron* **1997**, *53*, 2233; c) M. J. Crossley, T. W. Hambley, L. G. Mackay, A. C. Try, R. Walton, *J. Chem. Soc., Chem. Commun.* **1995**, 1077; d) E. Yashima, M. Akashi, N. Miyauchi *Chem. Lett.* **1991**, 1017; e) C. S. Wilcox, *Tetrahedron Lett.* **1985**, *26*, 5749.
- [5] a) J. C. Adrian, C. S. Wilcox, *J. Am. Chem. Soc.* **1992**, *114*, 1398; b) J. C. Adrian, C. S. Wilcox, *J. Am. Chem. Soc.* **1989**, *111*, 8055; c) M. D. Cowart, I. Sucholeiki, R. R. Bukownik, C. S. Wilcox, *J. Am. Chem. Soc.* **1988**, *110*, 6204.
- [6] S. H. Wilen, J. Z. Qi, *J. Org. Chem.* **1991**, *56*, 485.
- [7] a) B. Minder, M. Schürch, T. Mallat, A. Baiker, *Catalysis Lett.* **1995**, *31*, 143; b) Y. Goldberg, H. Alper, *Tetrahedron Lett.* **1995**, *36*, 369.
- [8] a) C. Wang, H. E. Hennis, *J. Heterocycl. Chem.* **1970**, *7*, 935; b) H. E. Hennis, L. R. Thompson, C. Wang, D. B. Priddy, *J. Org. Chem.* **1970**, *35*, 3127; c) H. E. Hennis, C. Wang, *J. Org. Chem.* **1969**, *34*, 1907.
- [9] B. Diab, H. Jolibois, A. Chambaudet, B. Laude, L. Ouahab, *J. Chem. Res. (S)* **1994**, 456.
- [10] a) P. de March, M. Moreno-Mañas, J. L. Roca, *J. Heterocycl. Chem.* **1986**, *23*, 1511; b) P. de March, M. Moreno-Mañas, R. Pleixats, J. L. Roca, *J. Heterocycl. Chem.* **1984**, *21*, 1369.
- [11] B. Talapatra, S. K. Mandal, K. Biswas, R. Chakrabarti, S. K. Talapatra, *J. Indian Chem. Soc.* **2001**, *78*, 765.
- [12] a) H. Leutbecher, L. A. D. Williams, H. Rösner, U. Beifuss, *Bioorg. Med. Chem. Lett.* **2007**, *17*, 978; b) H. Leutbecher, J. Conrad, I. Klaiber, U. Beifuss, *Synlett* **2005**, 3126; c) H. Leutbecher, J. Conrad, I. Klaiber, U. Beifuss, *QSAR Comb. Sci.* **2004**, *23*, 895.